The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) and the University of Oxford’s Jenner Institute collaborated to develop a new method of creating malaria vaccines, the agency said Tuesday.
This fourth case study will help create a viral vector, which researchers use to carry genetic material that will prevent or treat an individual disease.
“Viruses evolve and new vaccines need to be found to stop or inhibit their spread,” MHRA Director of Licensing Siu Ping Lam said. “It is important to ensure that academic institutions across the U.K. and beyond continue to innovate in their approaches to developing vaccines and medicines that can tackle threats from emerging viruses and improve the lives of people throughout the world. At MHRA we understand this and work hard to ensure institutions can come to us and get the very best scientific and regulatory advice, guidance and expertise at every step of the clinical product development lifecycle.”
MHRA facilitated the project through introductions between researchers at Jenner Institute and various agency teams, such as goods manufacturing practice inspectorate, clinical trials teams, toxicologists and pharmaceutical assessors. MHRA also provided feedback and information package descriptions.
“This work could have a huge impact on public health,” Oxford Clinical BioManufacturing Facility Qualified Person Eleanor Barrie said. “Using this approach, researchers at Oxford University have developed a panel of novel vaccines for early phase studies in the treatment of malaria and other diseases including HIV, TB and flu.”